|
Juggling
with quality tools for productivity
Indian pharma companises are increasingly focusing on the
adoption of comprehensive management tools for enhancing productivity
and overall improvement of the organisation. However, the
use of Six Sigma is yet to gain a foothold in the pharma industry,
says Sapna Dogra.
'CROs
have to strengthen their staff and infrastructure'
Dr Reddy's Laboratories is the talk of the pharma circles
since initiating 'Perlecan', its joint venture with CitiGroup
and ICICI Ventures. Deepali Gupta finds out from N R Srinivas,
Executive Vice President-Drug Development about opportunities
and challenges facing Indian CROs and pharma companies.
Glenmark
acquires marketing company in Argentina
Glenmark Pharmaceuticals SA (GPSA), a wholly owned Swiss subsidiary
of Glenmark Pharmaceuticals, acquired an Argentine marketing
company Servycal S A for an undisclosed consideration.
Nicholas
Piramal acquires Avecia Pharmaceuticals in UK
Nicholas Piramal India (NPIL) announced the acquisition of
Avecia Pharmaceuticals, UK for a consideration of £9.5
million. The consideration is inclusive of funding the business'
UK pension fund deficit of between £8-9 million.
Avesthagen,
TNO sign agreement in nutrigenomics
Avestha Gengraine Technologies (Avesthagen) and TNO Quality
of Life of the Netherlands, signed an agreement to join forces
in developing new products to combat obesity and related disorders.
AstraZeneca,
Nicholas Piramal clinch R&D pact
AstraZeneca AB, Sweden and Nicholas Piramal India (NPIL) announced
the signing of a development and know-how agreement. Under
the agreement, the companies will establish a framework for
future collaboration on development of processes for the manufacture
of intermediates, active ingredients or bulk drugs for supply
to AstraZeneca.
Stock
Watch
The pressure continues as pharma stocks post mixed results.
Pharma majors like Biocon, Ranbaxy, Cipla, Ipca, Dr Reddy`s
and Nicholas Piramal announced their results in the second
fortnight.
Indo-Japanese
conference on pharma research and technology
At the beginning of this fiscal Utkarsh Palnitkar, Director,
E&Y, said that this year is crucial for Indian pharma
companies to explore the untouched Japanese market and research
opportunities it has to offer. Indian companies have taken
the advice rather seriously.
|
